A Wuhan specialty clinical testing company building esoteric diagnostic assays and immune-repertoire technology for hematology and oncology.
Kindstar Biotech / Peking University First Hospital
Released September 11, 2026
Peptide-HLA class I binding predictor that deconvolves multi-allele immunopeptidomics, pairing frozen ESM-2 embeddings with attention-based MIL.